AKT1 and neoplasm: Treatment of EGFRvIII expressing HCC xenografts with the anti-EGFRvIII monoclonal antibody CH12 inhibited xenograft growth in vivo by suppressing tumor proliferation and angiogenesis and by reducing phosphorylation of constitutively active EGFRvIII, Akt, and ERK [208].